CSS
ADMA icon

Cubist Systematic Strategies’s ADMA Biologics ADMA Stock Holding History

Cubist Systematic Strategies’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$545K Sell
37,200
-200
-0.5% -$3.43K ﹤0.01% 2238
2025
Q2 		$681K Buy
+37,400
New +$763K ﹤0.01% 2126
2024
Q4 		– Sell
-11,400
Closed -$228K – 2914
2024
Q3 		$228K Buy
+11,400
New +$177K ﹤0.01% 2527

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cubist Systematic Strategies's ADMA Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 483,797 shares — an estimated $9.87M sold.

Cubist Systematic Strategies first reported a position in ADMA in Q1 2020 and held it in 14 quarters. The position peaked at $9.6M in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 483,797 ADMA Biologics shares in Q2 2025, an estimated $9.87M.
  • Cubist Systematic Strategies first reported a position in ADMA Biologics in Q1 2020 and held it in 14 quarters.
  • Cubist Systematic Strategies's ADMA Biologics position peaked at $9.6M in Q1 2025.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.